Tscan Therapeutics (TCRX) currently reports a ROE of -170.55%. That is below the Healthcare sector average of 21.28%. Use the charts on this page to explore Tscan Therapeutics's ROE history and peer comparisons.

Tscan Therapeutics's ROE of -170.55% is lower than the Healthcare sector average of 21.28%. That is roughly 901.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Tscan Therapeutics's current -170.55% should be judged against Healthcare norms (sector average: 21.28%) and against TCRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -170.55%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for Tscan Therapeutics, and consider following TCRX for alerts when major investors trade the stock.

Tscan Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -170.55% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TCRX with unrelated industries.